Indeed, genetic or pharmacologic inhibition of Notch1 enhanced trastuzumab (an anti-HER2 therapy) sensitivity and diminished recurrence from residual dormant breast cancer cells after trastuzumab treatment (Pandya et al., 2011). The gene discussed is ERBB2; the disease is breast carcinoma.